Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Throughout the last three months, 10 analysts have evaluated Adient (NYSE:ADNT), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 1 | 7 | 1 | 0 |
Last 30D | 0 | 0 | 0 | 1 | 0 |
1M Ago | 1 | 0 | 5 | 0 | 0 |
2M Ago | 0 | 1 | 2 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.1, a high estimate of $40.00, and a low estimate of $21.00. Observing a downward trend, the current average is 13.08% lower than the prior average price target of $32.33.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Adient. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Adam Jonas | Morgan Stanley | Lowers | Underweight | $21.00 | $32.00 |
Ryan Brinkman | JP Morgan | Lowers | Neutral | $27.00 | $31.00 |
Dan Levy | Barclays | Lowers | Equal-Weight | $24.00 | $29.00 |
Colin Langan | UBS | Lowers | Neutral | $24.00 | $27.00 |
John Murphy | B of A Securities | Lowers | Buy | $40.00 | $42.00 |
Ryan Brinkman | JP Morgan | Lowers | Neutral | $31.00 | $32.00 |
Dan Levy | Barclays | Lowers | Equal-Weight | $29.00 | $34.00 |
Colin Langan | UBS | Lowers | Neutral | $27.00 | $31.00 |
James Picariello | Exane BNP Paribas | Announces | Neutral | $26.00 | - |
Colin Langan | Wells Fargo | Lowers | Overweight | $32.00 | $33.00 |
Capture valuable insights into Adient's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Adient analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment into this new company. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated seating revenue from joint ventures after factoring in the sale was about $3.8 billion in fiscal 2023 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2023 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $15.4 billion and fiscal 2024 is forecast to about $14.6 billion.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Adient faced challenges, resulting in a decline of approximately -8.36% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Adient's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -0.3%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.55%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Adient's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.12%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.32, caution is advised due to increased financial risk.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ADNT